328 related articles for article (PubMed ID: 26980765)
21. Inhibition of cystine uptake disrupts the growth of primary brain tumors.
Chung WJ; Lyons SA; Nelson GM; Hamza H; Gladson CL; Gillespie GY; Sontheimer H
J Neurosci; 2005 Aug; 25(31):7101-10. PubMed ID: 16079392
[TBL] [Abstract][Full Text] [Related]
22. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
23. ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner.
Chen D; Fan Z; Rauh M; Buchfelder M; Eyupoglu IY; Savaskan N
Oncogene; 2017 Oct; 36(40):5593-5608. PubMed ID: 28553953
[TBL] [Abstract][Full Text] [Related]
24. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
26. Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT.
Wang Z; Ding Y; Wang X; Lu S; Wang C; He C; Wang L; Piao M; Chi G; Luo Y; Ge P
Cancer Lett; 2018 Aug; 428():21-33. PubMed ID: 29702192
[TBL] [Abstract][Full Text] [Related]
27. Glutamate, excitatory amino acid transporters, Xc- antiporter, glutamine synthetase, and gamma-glutamyltranspeptidase in human corneal epithelium.
Langford MP; Redmond P; Chanis R; Misra RP; Redens TB
Curr Eye Res; 2010 Mar; 35(3):202-11. PubMed ID: 20373878
[TBL] [Abstract][Full Text] [Related]
28. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Sehm T; Fan Z; Ghoochani A; Rauh M; Engelhorn T; Minakaki G; Dörfler A; Klucken J; Buchfelder M; Eyüpoglu IY; Savaskan N
Oncotarget; 2016 Jun; 7(24):36021-36033. PubMed ID: 27074570
[TBL] [Abstract][Full Text] [Related]
29. Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Garcia CG; Kahn SA; Geraldo LHM; Romano I; Domith I; Silva DCLE; Dos Santos Assunção F; Ferreira MJ; Portugal CC; de Souza JM; Romão LF; Netto ADP; Lima FRS; Cossenza M
Mol Neurobiol; 2018 Aug; 55(8):6816-6833. PubMed ID: 29349577
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target.
Albrecht P; Lewerenz J; Dittmer S; Noack R; Maher P; Methner A
CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):373-82. PubMed ID: 20053169
[TBL] [Abstract][Full Text] [Related]
31. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.
Chung WJ; Sontheimer H
J Neurochem; 2009 Jul; 110(1):182-93. PubMed ID: 19457125
[TBL] [Abstract][Full Text] [Related]
32. Propofol inhibits invasion and proliferation of C6 glioma cells by regulating the Ca
Wang XY; Li YL; Wang HY; Zhu M; Guo D; Wang GL; Gao YT; Yang Z; Li T; Yang CY; Chen YM
Toxicol In Vitro; 2017 Oct; 44():57-65. PubMed ID: 28663055
[TBL] [Abstract][Full Text] [Related]
33. The x(c)(-) cystine/glutamate antiporter (xCT) as a potential target for therapy of cancer: yet another cytotoxic anticancer approach?
Savaskan NE; Hahnen E; Eyüpoglu IY
J Cell Physiol; 2009 Aug; 220(2):531-2; author reply 533-4. PubMed ID: 19415694
[No Abstract] [Full Text] [Related]
34. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
[TBL] [Abstract][Full Text] [Related]
35. The role of system Xc
Dang DK; Shin EJ; Tran HQ; Kim DJ; Jeong JH; Jang CG; Nah SY; Sato H; Nabeshima T; Yoneda Y; Kim HC
Neurochem Int; 2017 Sep; 108():254-265. PubMed ID: 28457879
[TBL] [Abstract][Full Text] [Related]
36. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
37.
Yang H; Jenni S; Colovic M; Merkens H; Poleschuk C; Rodrigo I; Miao Q; Johnson BF; Rishel MJ; Sossi V; Webster JM; Bénard F; Schaffer P
J Nucl Med; 2017 Mar; 58(3):367-373. PubMed ID: 27789715
[TBL] [Abstract][Full Text] [Related]
38. Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues.
Martis RM; Knight LJ; Donaldson PJ; Lim JC
Oxid Med Cell Longev; 2020; 2020():4594606. PubMed ID: 32655769
[TBL] [Abstract][Full Text] [Related]
39. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
40. Expression and function of cystine/glutamate transporter in neutrophils.
Sakakura Y; Sato H; Shiiya A; Tamba M; Sagara J; Matsuda M; Okamura N; Makino N; Bannai S
J Leukoc Biol; 2007 Apr; 81(4):974-82. PubMed ID: 17200146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
